Dennis Dobard, MD
Psychiatry · Springfield, MONPI 1063554038
Payments from drug & device makers
Across 585 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Alkermes, Inc.$1K
- Supernus Pharmaceuticals, Inc.$865
- Neurocrine Biosciences, Inc.$830
- Johnson & Johnson$762
- plus $4K from 19 others
What the payments were for
- Food & beverage$9,96398%
- Education$1962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 100 | $1,421 |
| Vanda Pharmaceuticals Inc. | 82 | $1,194 |
| Alkermes, Inc. | 54 | $1,030 |
| Supernus Pharmaceuticals, Inc. | 48 | $865 |
| Neurocrine Biosciences, Inc. | 44 | $830 |
| Johnson & Johnson | 40 | $762 |
| Teva Pharmaceuticals USA, Inc. | 42 | $756 |
| Axsome Therapeutics, Inc. | 14 | $558 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $511 |
| AbbVie(2 entities) | 29 | $410 |
| E.r. Squibb & Sons, L.L.C. | 20 | $339 |
| Lundbeck LLC | 17 | $316 |
| Corium, LLC | 9 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $211 |
| Sunovion Pharmaceuticals Inc. | 11 | $161 |
| Eisai Inc. | 8 | $123 |
| Indivior Inc. | 6 | $113 |
| Avanir Pharmaceuticals, Inc. | 4 | $72 |
| Ironshore Pharmaceuticals Inc. | 3 | $61 |
| Merck | 4 | $53 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
| Tris Pharma Inc | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Avion Pharmaceuticals | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$251
- Auvelity$250
- ABILIFY MAINTENA$248
- ABILIFY ASIMTUFII$123
- Austedo XR$122
- INVEGA SUSTENNA$112
- INVEGA TRINZA$112
How this compares
$10,160 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 179 | $604,586 |
| AustedoDeutetrabenazine | 48 | $282,689 |
| IngrezzaValbenazine Tosylate | 30 | $264,305 |
| Abilify MaintenaAripiprazole | 58 | $162,293 |
| Invega TrinzaPaliperidone Palmitate | 11 | $101,300 |
| AristadaAripiprazole Lauroxil | 36 | $94,346 |
| RexultiBrexpiprazole | 68 | $90,021 |
| FanaptIloperidone | 27 | $77,442 |
| Chlorpromazine Hcl | 319 | $64,975 |
| Asenapine Maleate | 120 | $43,155 |
| Divalproex Sodium ErDivalproex Sodium | 480 | $40,276 |
| Lurasidone Hcl | 207 | $26,882 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $24,830 |
| Clomipramine Hcl | 220 | $24,782 |
| Clozapine | 241 | $23,551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $762 | $705,886190 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $756 | $294,873315 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $830 | $264,30530 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,421 | $252,314126 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,030 | $119,17651 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,194 | $77,44227 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $211 | $33,40854 claims |
| MerckBelsomra | $53 | $20,52447 claims |
| AbbVieVraylar | $410 | $17,03313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Springfield
- Alok JainSpringfield$64K
- Lorri DarrowSpringfield$47K
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
- Howard IlivickySaint Charles$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.